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The transporter associated with antigen processing (TAP) delivers the 25 
viral proteolytic products generated by the proteasome in the cytosol to the 26 
endoplasmic reticulum lumen that are subsequently recognized by cytotoxic T 27 
lymphocytes (CTL). However, several viral epitopes have been identified in 28 
TAP-deficient models. Using mass spectrometry to analyze complex human 29 
leukocyte antigen (HLA)-bound peptide pools isolated from large numbers of 30 
TAP-deficient vaccinia virus-infected cells, we identified eleven ligands naturally 31 
presented by four different HLA-A, -B, and -C class I molecules. Two of these 32 
ligands were presented by two different HLA class I alleles, and thus, thirteen 33 
different HLA/peptide complexes were formed simultaneously in the same 34 
vaccinia-infected cells. In addition to the high-affinity ligands, one low-affinity 35 
peptide restricted by each of the HLA-A, -B and -C class I molecules was 36 
identified. Both high- and low-affinity ligands generated long-term memory CTL 37 
responses against vaccinia virus in an HLA-A2 transgenic mouse model. The 38 
processing and presentation of two vaccinia virus-encoded HLA-A2-restricted 39 
antigens could take place via proteasomal and non-proteasomal pathways, 40 
which were blocked in infected cells with chemical inhibitors specific for different 41 
subsets of metalloproteinases. These data have implications for the study of the 42 
effectiveness of early empirical vaccination with cowpox virus against smallpox 43 




The eradication of smallpox, a disease caused by variola major virus, 47 
was made possible by early empirical, cross-protective vaccination with cowpox 48 
virus and later through the massive worldwide production and administration of 49 
vaccinia virus (VACV) (17). The Orthopoxvirus vaccinia is a widely used tool for 50 
research and vaccine development (46), and recent concerns about 51 
bioterrorism and emerging infectious diseases have elicited renewed interest in 52 
VACV and other poxviruses (30). Vaccination induces a strong humoral 53 
response leading to viral clearance, and the role of cellular responses in this 54 
cross-protection is well documented (20),(55). In recent years, studies in both 55 
vaccinated humans and human histocompatibility complex (HLA)-transgenic 56 
mouse models have allowed the identification of more than 70 VACV-derived 57 
epitopes restricted by various HLA molecules (reviewed in (31),(29)).  58 
In cellular immunity, the recognition and killing of infected cells by CD8+ 59 
cytolytic T lymphocytes (CTLs) first requires viral proteins to be proteolytically 60 
degraded (73). Antigen processing generates short peptides that are 61 
translocated to the endoplasmic reticulum lumen by transporter associated with 62 
antigen processing (TAP) and then assembled with newly synthesized β2-63 
microglobulin and HLA class I heavy chain. Despite initial assumptions that the 64 
multi-catalytic and ubiquitous proteasome was the only protease fully capable of 65 
generating peptide ligands for presentation on HLA class I molecules, several 66 
studies have demonstrated that a growing number of alternative pathways 67 
contribute to endogenous antigen processing (reviewed in (12),(26)). 68 
Individuals with mutations in the TAP gene that generate non-functional 69 
TAP complexes have been described (reviewed in (8)). Patients with this HLA 70 
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class I deficiency may appear asymptomatic for long periods of their lives. TAP-71 
deficient patients do not seem particularly susceptible to viral infections or 72 
neoplasms. Therefore, their immune systems must be reasonably efficient, and 73 
antibodies, NK cells, CD8+ γδ T cells, and the reduced cytolytic CD8+ αβ T 74 
subpopulation that is specific for TAP-independent antigens may all contribute 75 
to immune defenses that protect against severe viral infections in these 76 
individuals. In addition, several strains of viruses, including cowpox virus (1), 77 
have found ways to obstruct TAP expression or function in order to prevent 78 
CTLs from identifying infected cells (reviewed in (35)); therefore, the TAP-79 
independent pathways must be important for killing cells infected with these 80 
viruses. The identification of TAP-independent epitopes conserved among 81 
orthopoxviruses could also be relevant to the study of the mechanisms of early 82 
empirical vaccination against smallpox disease performed with cowpox virus. 83 
Although TAP-independent viral epitopes are known (reviewed in (35)), 84 
there is a marked absence of methodical studies of TAP-independent 85 
epitopes/ligands restricted by different HLA molecules in cells infected with a 86 
single virus. Moreover, in all previous studies, very limited antigen processing 87 
capacity has been reported in TAP-deficient cells.  Therefore, is only one TAP-88 
independent ligand/epitope restricted by a single HLA molecule exposed on the 89 
cell membrane surface, as suggested by these studies? Conversely, could a 90 
TAP-deficient cell bind several viral ligands to different HLA molecules 91 
simultaneously? We are interested in the identification of viral ligands presented 92 
by several common HLA antigens in TAP-deficient infected cells. Using 93 
immunoproteomic analysis, we compared HLA ligands isolated from large 94 
numbers of healthy or VACV-infected cells. This study identified eleven TAP-95 
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independent, naturally processed ligands from eight different VACV proteins in 96 
infected cells that were mostly conserved among the Orthopoxviridae family, 97 
including cowpox virus. 98 
99 
 6 
MATHERIALS AND METHODS 100 
Mice 101 
H-2 class I knockout HLA-A*0201-transgenic mice (19) were bred in our 102 
animal facilities in strict accordance with the recommendations in the Guide for 103 
the Care and Use of Laboratory Animals of the Spanish government regulations 104 
(accreditation number 28079-34A). The protocol was approved by the 105 
Committee on the Ethics of Animal Experiments of the Institute of Health 106 
“Carlos III” (Permit Number: PI-283). All surgery was performed under sodium 107 
pentobarbital anesthesia, and all efforts were made to minimize suffering. 108 
Cell lines  109 
T2 cells, a line of TAP-deficient human cells that express HLA-A2, -B51, 110 
and -Cw1 class I molecules on their surface (57), were transfected with HLA-111 
B27 (a gift from Dr. David Yu, University of California, Los Angeles, CA). The 112 
mouse cell lines RMA (TAP positive) and RMA-S (TAP negative) were 113 
transfected with HLA-A*0201 α1α2 domains, and the mouse H-2Db α3 114 
transmembrane and cytoplasmic domains have been previously described (51). 115 
The RMA-S transfectant cells expressing HLA-B*2705 have been previously 116 
described (66). All cell lines were cultured in RPMI 1640 supplemented with 117 
10% fetal bovine serum and 5 µM β-mercaptoethanol.  118 
Synthetic peptides. 119 
Peptides were synthesized in a peptide synthesizer (model 433A; 120 
Applied Biosystems, Foster City, CA) and purified by reverse-phase HPLC. The 121 
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correct molecular mass of the peptides was established by MALDI-TOF MS, 122 
and their correct composition was determined by quadrupole ion trap 123 
microHPLC.  124 
Inhibitors.  125 
Brefeldin A (BFA) and all protease inhibitors were purchased from 126 
Sigma-Aldrich, except for leupeptin (Amersham-UBS), pepstatin (Boehringer 127 
Mannheim), Z-VAD.fmk (Enzyme System Products, CA, USA), (z-LL)2 ketone 128 
(Merck), and lactacystin (Dr. E. J. Corey, Harvard University). The specificity 129 
and activity of all inhibitors used in this study were summarized in Table 1. For 130 
control of activity of the protease inhibitors, RMA-HLA-A*0201 cells (1 x 108) 131 
were disrupted by sonication for 15 min at 4ºC, and centrifuged as previously 132 
reported (39). A supernatant aliquot corresponding to 1 x 107 cells was directly 133 
frozen (non-degraded control). Equivalent aliquots were incubated in the 134 
presence of individual inhibitors at 200 M and digestion by cellular proteases 135 
was allowed for 5 days at 37ºC in PBS. Inhibitors were renewed daily. A sample 136 
incubated without inhibitors was taken as the degraded control. After SDS-137 
PAGE separation and Coomassie Blue staining of these samples, the overall 138 
protein content of each lane was quantitated by densitometry with the TINA 139 
2.09e program (Isopenme geräte, GmbH, Germany). % Inhibition of protein 140 
degradation caused by each inhibitor was calculated as follows: 100 x (sample 141 
with inhibitor – degraded)/(non-degraded – degraded). 142 
 143 
Infection of the T2-B27 cell line by VACV 144 
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1-3 x 109 T2-B27 cells were infected with VACV at a multiplicity of 145 
infection of 10 plaque-forming units/cell in 10 ml, incubated for 2 h at 37ºC and 146 
then washed. The cells were then cultured for 24 h and stained with the 147 
Omnitope antiserum-FITC that recognizes VACV purified virions. Samples were 148 
analyzed by FACS. Later the cells were frozen. 149 
 150 
Isolation of HLA-bound peptides.  151 
HLA-bound peptides were isolated from 4 x 1010 healthy or VACV-WR-152 
infected T2-B27 transfectant cells. Cells were lysed in 1% CHAPS (Sigma), 20 153 
mM Tris/HCl buffer, and 150 mM NaCl, pH 7.5, in the presence of a protease 154 
inhibitor cocktail (23). HLA-peptide complexes were isolated via affinity 155 
chromatography of the soluble fraction of cell extracts with the following mAbs, 156 
used sequentially: PA2.1 (anti-HLA-A2) (50), ME1 (anti-HLA-B27) (13), and 157 
W6/32 (specific for a monomorphic HLA class I determinant) (5) (Figure 1). 158 
HLA-bound peptides were eluted at room temperature with 0.1% aqueous 159 
trifluoroacetic acid (TFA), separated from the large subunits and concentrated 160 
with a Centricon 3 column (Amicon, Beverly, MA) exactly as previously 161 
described (23). 162 
Electrospray-ion trap mass spectrometry analysis. 163 
 164 
Peptide mixtures recovered after the ultra-filtration step were 165 
concentrated using Micro-Tip reversed-phase columns (C18, 200 µl, Harvard 166 
Apparatus, Holliston, MA) (23). Each C18 tip was equilibrated with 80% 167 
acetonitrile in 0.1% TFA, washed with 0.1% TFA, and then loaded with the 168 
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peptide mixture. The tip was then washed with an additional volume of 0.1% 169 
TFA, and the peptides were eluted with 80% acetonitrile in 0.1% TFA. Peptide 170 
samples were then concentrated to about 18 µl using vacuum centrifugation 171 
(23).  172 
HLA class I peptides immunoprecipitated with each HLA-specific mAb 173 
were analyzed in three different HPLC runs by µLC-MS/MS using an Orbitrap 174 
XL mass spectrometer (Thermo Electron, San Jose, CA) fitted with a capillary 175 
HPLC column (Eksigent, Dublin, CA) (23). The peptides were resolved on 176 
homemade Reprosil C18 capillary columns (75 micron ID) (24) with a 7-40% 177 
acetonitrile gradient for 2 h in the presence of 0.1% formic acid. The seven 178 
most intense masses that exhibited single-, double-, and triple-charge states 179 
were selected for fragmentation from each full mass spectrum by CID.  180 
 181 
Database searches. 182 
 183 
Sequest 3.31 (Thermo-Fisher) (14) was used for peak-list generation of 184 
the µLC-MS/MS data. The peaks were identified by using Proteome Discoverer 185 
1.0 SP1 (Thermo-Fisher), combining the results of Sequest 3.31 and Bioworks 186 
Browser 3.3.1 SP1 (Thermo-Fisher) (14), and using the human and virus parts 187 
of the NCBI database (Jan 2009), which includes 656,486 proteins. The search 188 
was not limited by enzymatic specificity, the peptide tolerance was set to 0.005 189 
Da, and the fragment ion tolerance was set to 0.5 Da (23),(42). This search was 190 
not limited by any methodological bias (selection of individual protein, use of 191 
HLA consensus scoring algorithms, etc.). Identified peptides were selected if 192 
the following criteria were met: Sequest Xcorr >1.4 for singly, >2.2 for doubly, 193 
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and >2.9 for triply charged peptides; P(pep) less than 1 x 10-3; and mass 194 
accuracy of 0.005 Da (23),(42). When the MS/MS spectra fitted more than one 195 
peptide, only the highest scoring peptide was analyzed. No peptides were 196 
found in a search of a reversed database. The purpose of the filtering criteria 197 
was to identify candidate vaccinia virus peptide MS/MS scans for further 198 
manual inspection to determine whether the MS/MS fragment ion fingerprint 199 
matched the identified peptide sequence. In addition, the corresponding 200 
synthetic peptide was made, and its MS/MS spectrum was used to confirm the 201 
assigned sequence.  202 
 203 
MHC/peptide stability assays. 204 
 205 
The following synthetic peptides were used as controls in complex 206 
stability assays: KPNA2 (GLVPFLVSV, HLA-A2-restricted) (22), Flu NP 207 
(SRYWAIRTR, HLA-B27-restricted) (67), HBV HBc19-27 (LPSDFFPSV, HLA-208 
B51-restricted) (7), CMV pp657-15 (RCPEMISVL, HLA-Cw1-restricted) (32), and 209 
C4CON (QYDDAVYLK, HLA-Cw4-restricted) (16). Either RMA-S transfectants 210 
or T2 cells expressing low amounts of MHC class I on the cell surface were 211 
incubated at 26°C for 16 h in RPMI 1640 medium supplemented with 10% heat-212 
inactivated fetal bovine serum (FBS). This allows the expression of empty MHC 213 
class I molecules (without antigenic peptide) that are stable only at 26ºC, but 214 
not at 37ºC, on the cell membrane. The cells were washed and incubated for 215 
2 h at 26 °C with various concentrations of peptide in the same medium. 216 
Afterward, the cells were kept at 37 °C and collected for flow cytometry after 217 
4 h. This assay allows for the internalization of empty MHC class I molecules 218 
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and can therefore discriminate between bound and unbound peptides. HLA 219 
expression levels were measured using the Abs monoclonal PA2.1 (anti-HLA-220 
A2), monoclonal ME1 (anti-HLA-B27), polyclonal H00003106-B01P (specific for 221 
HLA-B class I molecules) (Abnova, Taipei, Taiwan), and polyclonal SC-19438 222 
(specific for HLA-C class I molecules) (Santa Cruz Biotechnology, Santa Cruz, 223 
CA) as previously described (40). Samples were acquired on a FACSCanto flow 224 
cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using CellQuest 225 
Pro 2.0 software (BD Bioscience). Cells incubated without peptides had peak 226 
fluorescence intensities close to background staining with secondary Ab alone. 227 
The fluorescence index (FI) was calculated as the ratio of the mean channel 228 
fluorescence of the sample to that of control cells incubated without the 229 
peptides. The binding of peptides was also expressed as the EC50, which is the 230 
molar concentration of the peptides producing 50% of the maximum 231 
fluorescence obtained at a concentration range between 0.001 and 100 µM.  232 
 233 
Magnetic antigen cell separation (MACS) 234 
 235 
Mouse T lymphocytes were isolated by the depletion of non-T CD8+ cells 236 
(negative selection) using the T CD8a+ Cell Isolation Kit (Miltenyi Biotec GmbH, 237 
Gladbach, Germany) according to the manufacturer’s specifications. The purity 238 
of the cell preparations recovered after negative selection was verified by 239 
fluorescence-activated cell sorting (FACS) and found to be higher than 95% for 240 
CD8+ T lymphocytes (56).  241 
 242 
Ex vivo intracellular cytokine staining (ICS) 243 
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 244 
Intracellular cytokine staining assays were performed as described 245 
previously (58). Purified CD8+ T lymphocytes were obtained from HLA-A*0201 246 
transgenic mice up to 30 days (memory) post i.p. infection with 1 x 107 PFU 247 
VACV-WR, stimulated for 2 h with either RMA or RMA-S HLA-A*0201 cells 248 
infected with VACV-WR, and incubated overnight in the presence of 5 µg/ml 249 
BFA. Later, cells were incubated with FITC-conjugated anti-CD8 mAb 250 
(ProImmune, Oxford, UK) for 30 min at 4°C, fixed with Intrastain kit 251 
(DakoCytomation, Glostrup, Denmark) reagent A, and incubated with PE-252 
conjugated anti-IFN-γ mAb (BD PharMingen, San Diego, CA) in the presence of 253 
Intrastain kit permeabilizing reagent B for 30 min at 4°C. Events were acquired 254 
and analyzed as MHC/peptide stability assays.  255 
 256 
T cell lines, cytotoxicity assays, and ICS  257 
Polyclonal SIINFEKL or VACV peptide-monospecific CTLs were 258 
generated by immunizing mice i.p. with 1 x 107 PFU VACV-OVA257–264 encoding 259 
the miniprotein MSIINFEKL or VACV-WR as previously described (44),(39), 260 
respectively. Splenocytes from immunized mice were re-stimulated in vitro with 261 
mitomycin C-treated spleen cells pulsed with 10-6 M of the respective peptide 262 
and cultured in α-MEM supplemented with 10% FBS, 1x10-7 M peptide and 1% 263 
2-ME. Recombinant human interleukin-2 for the long-term propagation of 264 
peptide-specific CTL lines was generously provided by Hoffmann-LaRoche. The 265 
RMA-HLA-A*0201 cells were used as target cells in standard 4 h cytolytic 266 
assays (39).  267 
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ICS assays to detect the recognition of infected cells by polyclonal CTL 268 
cell lines were performed as previously described (9). CTL lines were stimulated 269 
for 4 h in the presence of 5 μg/ml BFA and target cells that had been infected 270 
with VACV or VACV-OVA257–264 overnight. When protease inhibitors were used, 271 
all drugs were added 15 min before the virus and kept at a 5-fold higher 272 
concentration during the 1 hr adsorption period than throughout the infection. 273 
After washing the virus inoculum, the inhibitors were kept at the concentrations 274 
indicated for the individual experiments. The inhibitors were not toxic at the 275 
indicated concentrations since they not affect either antigen presentation both 276 
the A10L688-696 and A17L9-17 epitopes (see below) or VACV infection when the 277 
Omnitope antiserum with specifity for VACV proteins from purified virions 278 
(ViroStat Inc., Portland, ME) was used (Supplemental Fig. 1). The ICS with 279 
polyclonal CTL was performed similarly to ex vivo ICS. 280 
 281 
In vivo cytotoxicity assay 282 
In vivo cytotoxicity assays were performed as published (44). Spleens 283 
were obtained, erythrocytes were removed, and HLA-A*0201 splenocytes were 284 
split in two populations and labeled with either a high concentration (5 μM) or a 285 
low concentration (0.5 μM) of CFSE. After washing excess CFSE, CFSEhigh 286 
spleen cells were pulsed with 10−6 M VACV peptides for 30 min at 37°C. Excess 287 
peptide was washed at least twice, and CFSEhigh peptide-pulsed cells were 288 
mixed with equal numbers of CFSElow cells. A total of 8 × 106 cells of the spleen 289 
cells  mixed suspension were i.p. injected into each HLA-A*0201-transgenic 290 
mouse, which had been infected or not with i.p. 1 x 107 PFU VACV-WR 7 days 291 
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earlier. Two days later, the peritoneal cavity was lavaged, and spleens were 292 
extracted, and the cells were analyzed by flow cytometry to measure in vivo 293 
killing, using a FACSCanto flow cytometer. Data were analyzed using CellQuest 294 
Pro 2.0 software. Specific lysis was calculated as published (44) according to 295 
the formula: [1 − (ratio unprimed/ratio primed) × 100], where the ratio unprimed 296 
is %CFSElow/%CFSEhigh cells remaining in control uninfected recipients, and the 297 
ratio primed is %CFSElow/%CFSEhigh cells remaining in experimental infected 298 
recipients.  299 
300 
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RESULTS  301 
 302 
VACV-specific CD8+ T cells recognize TAP-deficient HLA-A*0201-303 
transfected cells. 304 
 305 
As the first step in the study of TAP-independent HLA-restricted 306 
responses to vaccinia virus, HLA-A*0201 transgenic mice were immunized with 307 
the virus. Next, the VACV-specific CD8+ response was evaluated using by 308 
intracellular cytokine staining (ICS) assays. A strong ex vivo response (50.1 ± 309 
9.4% of CD8+ cells secreted IFNγ) specific for this virus was detected in TAP+ 310 
target cells (Fig. 2, left panel). Additionally, a small fraction of VACV-specific 311 
CD8+ T lymphocytes recognized infected TAP-deficient cells (3.8 ± 0.8% of 312 
CD8+ cells secreted IFNγ, Fig. 2, right panel). These data indicate the 313 
existence of a TAP-independent antigen processing pathway(s) of some 314 
vaccinia virus epitopes in infected cells that could be recognized by specific 315 
CD8+ T lymphocytes. 316 
 317 
Physiological processing generates three different viral HLA-A2 318 
ligands in human TAP-deficient vaccinia-infected cells. 319 
 320 
HLA-A2-bound peptide pools were isolated from large numbers of either 321 
healthy or VACV-infected human TAP-deficient cells (110 ± 20 of MFI in VACV 322 
infected cells vs 15 ± 5 in healthy cells stained with an anti-VACV antiserum). 323 
These peptide mixtures were subsequently separated by reverse-phase HPLC 324 
and analyzed by mass spectrometry. Using bioinformatics tools, three 325 
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fragmentation spectra present in the VACV-infected HLA-A2-bound peptide 326 
pool, but absent from the control uninfected pool, were resolved with high 327 
confidence parameters as peptides of vaccinia virus proteins. A human 328 
proteome database search failed to identity any of these spectra as human 329 
protein fragments, confirming the viral origin of these peptides. The first ion 330 
peak, with an m/z of 926.4, was assigned to the viral amino acid sequence 331 
MLDDFSAGA, spanning residues 9-17 of the A17L protein of vaccinia virus 332 
(Supplemental Fig. 2, upper panel). In addition, two different ion peaks at m/z 333 
974.6 and 514.8 were assigned to peptides of the same viral protein. These ion 334 
peaks corresponded to SPEGEETII (Supplemental Fig. 2, medium panel) and 335 
ILDRIITNA (Supplemental Fig. 2, lower panel) peptides, which span residues 336 
614-623 and 688-696, respectively, of the A10L protein. Virtually all significant 337 
fragments of the three MS/MS spectra were assigned as daughter ions of the 338 
putative peptidic sequences (Supplemental Fig. 2). This theoretical assignment 339 
was confirmed by identity with the MS/MS spectrum of the corresponding 340 
synthetic peptide (Supplemental Fig. 2). Therefore, these results indicate that a 341 
total of three TAP-independent HLA-A2 ligands were endogenously processed 342 
and presented in the VACV-infected cells. 343 
 344 
Binding affinity of TAP-independent vaccinia virus ligands for the 345 
A*0201 molecule. 346 
 347 
The classical anchor motifs for HLA-A*0201 binding, Leu or Met at 348 
position 2 (P2) and aliphatic C-terminal residues (SYFPEITHI database: 349 
http://www.syfpeithi.de (53)), were present in two of the three detected TAP-350 
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independent viral ligands. In contrast, the ligand A10L614-623 presented Pro at 351 
P2, although it was co-immunoprecipitated with an HLA-A2-specific mAb and 352 
thus could be an unusual HLA-A2-restricted ligand. To confirm that HLA-A*0201 353 
was the MHC class I molecule that presented these ligands, MHC/peptide 354 
complex stability assays were performed using TAP-deficient RMA-S cells 355 
transfected with the HLA-A*0201 molecule (Fig. 3). The two viral ligands with 356 
HLA-A2 anchor motifs, A10L688-696 and A17L9-17, bound to HLA-A*0201 class I 357 
molecules with EC50 values in the range commonly found among other natural 358 
high-affinity ligands (Fig. 3B). In contrast, the HLA affinity was substantially 359 
lower for the A10L614-623 ligand, as the absence of HLA-A2 anchor motifs 360 
suggested; therefore, this peptide must be considered a low-affinity ligand. 361 
These data confirm that all ligands detected in vaccinia virus-infected cells were 362 
endogenously presented in association with the A*0201 molecule. 363 
 364 
Three viral HLA-B*2705 ligands were endogenously processed in 365 
human TAP-deficient vaccinia virus-infected cells. 366 
 367 
To date, about 60 human TAP-independent MHC class I ligands are 368 
known (35),(70), and these are mostly restricted by HLA-A2 and derived from 369 
the cleavage of signal sequences generated by the SPase complex. The 370 
A*0201-restricted CTL epitopes of vaccinia virus that we detected in TAP-371 
deficient cells could therefore be exceptional, and TAP-independent antigen 372 
processing pathways might be unable to generate vaccinia virus peptides that 373 
could bind to other HLA class I molecules. HLA-B27, which was previously 374 
described as an allele with high TAP dependency (2), was used to obtain 375 
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peptide pools from either healthy or VACV-infected TAP-deficient cells, as used 376 
to identify HLA-A*0201 ligands. Again, three fragmentation spectra present in 377 
the VACV-infected, HLA-B27-bound peptide pool, but absent from the control 378 
uninfected pool, were also resolved as peptides of vaccinia virus proteins. The 379 
human proteome database search failed to identify these spectra as human 380 
protein fragments, confirming the viral origin of these HLA-B27-bound peptides. 381 
The first ion peak, with an m/z of 428.8, was assigned to the viral amino acid 382 
sequence SRGYFEHMKK, spanning residues 867-876 of the A10L protein of 383 
vaccinia virus (Supplemental Fig. 3, upper panel), indicating that antigen 384 
processing of this protein could generate several viral ligands bound to two 385 
different HLA class I molecules. The second ion peak, at m/z 567.6, was 386 
assigned to the peptidic sequence YRLQGFTNAGIVAYK (Supplemental Fig. 3, 387 
medium panel), which spans residues 16-30 of the K2L protein. Finally, the third 388 
ion peak, at m/z 471.8, corresponded to a WQTMYTN peptide (Supplemental 389 
Fig. 3, lower panel), which spans residues 53-59 of the B8R protein. 390 
Supplemental Fig. 3 shows that all significant fragments of these three MS/MS 391 
spectra were assigned as daughter ions of the putative peptidic sequences. As 392 
HLA-A2 ligands, these assignments were confirmed by identity with the MS/MS 393 
spectrum of the corresponding synthetic peptide (Supplemental Fig. 3). In 394 
addition, the K2L16-30 ligand was also identified as a molecular ion at m/z +2 395 
(Supplemental Fig. 5). Collectively, these results indicate that a similar number 396 
of TAP-independent ligands were endogenously processed and presented by 397 
HLA-A2 or –B27 class I molecules in the same vaccinia virus-infected cells. 398 
 399 
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Binding affinity of TAP-independent vaccinia virus ligands for the 400 
B*2705 molecule. 401 
 402 
The A10L867-876 and K2L16-30 (but not B8R53-59) peptides have the known 403 
anchor motifs for HLA-B*2705 binding Arg at P2 and basic or aliphatic C-404 
terminal residues (SYFPEITHI database (53)). As the B8R53-59 peptide was also 405 
co-immunoprecipitated with an HLA-B27-specific mAb, it could be an unusual 406 
HLA-B27-restricted ligand. To confirm that HLA-B*2705 is the MHC class I 407 
molecule that presents these ligands, MHC/peptide complex stability assays 408 
were performed using TAP-deficient RMA-S cells transfected with the HLA-409 
B*2705 molecule (Figure 4). The two viral ligands with HLA-B27 anchor motifs, 410 
A10L867-876 and K2L16-30, bound to HLA-B*2705 class I molecules with
 EC50 411 
values to similar those of other natural high-affinity ligands (Fig. 4B). In contrast, 412 
the HLA affinity was substantially lower for the B8R53-59 ligand, as suggested by 413 
the absence of HLA-B27 anchor motifs, and this peptide could be considered a 414 
low-affinity ligand. These data confirm that the ligands detected in vaccinia 415 
virus-infected cells were endogenously presented in association with the 416 
B*2705 molecule. In summary, either HLA-A*0201 or B*2705 class I molecules 417 
can bind both high- and low-affinity ligands derived from different vaccinia virus 418 
proteins.  419 
 420 
Six vaccinia virus ligands were endogenously presented by HLA-421 
B51 and/or –Cw1 class I molecules in human TAP-deficient cells. 422 
 423 
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Given that several TAP-independent viral ligands were identified in 424 
association with either HLA-A*0201 or B*2705 class I molecules (see above), 425 
we investigated the possibility of new vaccinia virus ligands being presented by 426 
other HLA class I molecules expressed in the same T2 cells. As in the previous 427 
two analyses, six fragmentation spectra were found in the VACV-infected 428 
peptide pool that were absent from the uninfected control pool, and these 429 
spectra were also resolved as peptides of vaccinia virus proteins. Furthermore, 430 
the human proteome database search also failed to identify these spectra as 431 
human protein fragments, confirming the viral origin of these HLA-bound 432 
peptides. Supplemental Figures 4 and 5 show the experimentally obtained 433 
MS/MS spectra and their respective assignments. Each putative peptidic 434 
sequence was confirmed by identity with the MS/MS spectrum of the 435 
corresponding synthetic peptide (Supplemental Fig. 4 and 5). Five of these 436 
peptides were new viral sequences: IAMKRTLLEL (D5R 148-157), LPFGSLGI 437 
(A50R 294-301), IPSPGIMLV (C11R 101-110), MLDDFSAGAGVLDKDL (A17L 9-25), 438 
and DGLIIISI (D8L 112-119). Surprisingly, the K2L16-30 ligand previously detected 439 
in association with HLA-B*2705 (Supplemental Figure 3) was also 440 
immunoprecipitated in the third round with the W6/32 Ab. As HLA-A2, - B51, 441 
and –Cw1 present peptides with similar anchor motifs (SYFPEITHI database, 442 
(53)), HLA/peptide complex stability assays were performed to confirm that the 443 
sequential immunoprecipitation was performed correctly and to exclude the 444 
possibility that residual HLA-A2-bound ligands that were not fully 445 
immunoprecipitated with the PA2.1 (anti-HLA-A2) Ab in the first round would be 446 
immunoprecipitated in the third round with the W6/32 Ab (specific for a 447 
monomorphic HLA class I determinant). Figure 5A shows that, in contrast to the 448 
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positive control KPNA2 peptide, binding of HLA-A2 complexes to these six 449 
ligands was not detected. Therefore, these viral ligands do not bind to HLA-A2, 450 
which validates the experimental strategy used. In addition, to identify the HLA 451 
restriction of these ligands, new HLA/peptide complex stability assays using 452 
TAP-deficient T2 cells with specific anti-HLA-B or -C Abs were performed. The 453 
numbers of HLA-peptide surface complexes induced by the IAMKRTLLEL 454 
(D5R148-157), LPFGSLGI (A50R294-301), and IPSPGIMLV (C11R101-110) synthetic 455 
peptides were similar to those induced by a well-known HLA-B51 ligand, HBV 456 
HBc19-27 (Fig. 5B), using the anti-HLA-B Ab, indicating that these peptides were 457 
restricted by the HLA-B51 class I molecule. HLA stabilization was detected 458 
using anti-HLA-C (Fig. 5C) Ab with IPSPGIMLV (C11R 101-110), 459 
MLDDFSAGAGVLDKDL (A17L 9-25), and DGLIIISI (D8L 112-119), indicating that 460 
these peptides are restricted by the HLA-Cw1 allele. In addition, the K2L16-30 461 
ligand also bound to HLA-B*2705 (Supplemental Fig. 3 and Figure 4) was 462 
positive in their binding to HLA-Cw1 class I molecule justifying their dual 463 
immunoprecipitation (Figure 5). Five of these six viral ligands bound to HLA-B51 464 
(Fig. 5D) or –Cw1 (Fig. 5E) class I molecules with EC50 values similar to those 465 
of other natural high-affinity ligands. The only exception was the K2L16-30 466 
peptide, which showed a substantially lower affinity for HLA-Cw1, indicating that 467 
this peptide could be considered a low-affinity ligand (Fig. 5E). 468 
 469 
Thirteen natural peptide-HLA class I complexes were formed 470 
simultaneously in the same infected TAP-deficient cells. 471 
 472 
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A total of eleven viral ligands were identified bound to the four HLA class 473 
I molecules expressed in the T2 cells (summarized in Table 2). Similar numbers 474 
of ligands (3 or 4) were identified in association with HLA class I molecules 475 
previously described as having low (HLA-A2), high (HLA-B27) or unknown 476 
(HLA-B51 and –Cw1) TAP dependency. The same N-terminal core peptide, 477 
MLDDFSAGA, was found in two different ligands, A17L9-17 and A17L9-25, bound 478 
to HLA-A2 and –Cw1, respectively. Ten sequences were new vaccinia HLA 479 
ligands. Most were restricted by a single HLA allele, but two ligands, K2L16-30 480 
and C11R101-110, were found to be associated with two different alleles, HLA-481 
B27 and –Cw1 or HLA-B51 and –Cw1, respectively. This implies that thirteen 482 
different natural peptide-HLA class I complexes were formed simultaneously in 483 
the same infected TAP-deficient cells.  484 
Conservation of ligands among the Orthopoxvirus family. 485 
The sequences of eleven vaccinia virus ligands identified in the WR 486 
strain were compared with homologs derived from various poxviruses. This 487 
comparison included the Copenhagen and MVA strains of VACV, two strains of 488 
human poxvirus (variola major and variola minor), and other mammalian 489 
poxviruses, such as camelpox, cowpox, ectromelia virus, horsepox, 490 
monkeypox, rabbitpox, and taterapox. This study revealed the high degree of 491 
conservation of the ligands among orthopoxviruses (Table 3). Ten of these 492 
eleven ligands are almost fully conserved in the variola major and minor 493 
viruses, with a minor substitution in the P7 position of the C11R101-110 sequence. 494 
Only 60% of the previously described TAP+ vaccinia virus epitopes are 495 
conserved in the variola proteome (49),(52),(45) , indicating that TAP-496 
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independent vaccinia ligands are more highly conserved than TAP-dependent 497 
epitopes between immunogenic and pathologic poxviruses. 498 
Low hydrophobicity in TAP-independent vaccinia virus ligands. 499 
Eight TAP-independent epitopes, restricted by four different HLA class I 500 
molecules, were previously characterized in the Epstein-Barr virus (EBV) CTL 501 
response (reviewed in (37)). For this virus, only peptides from the BRLF1 and 502 
LMP2 proteins with high hydrophobicity are TAP independent (36),(37). 503 
Therefore, we tested this correlation in our vaccinia virus system. The 504 
hydrophobicity of all TAP-independent EBV epitopes was up to 2.1 on the grand 505 
average of hydropathicity (GRAVY) scale, with the maximum value found for the 506 
EBV LMP2 LLWTLVVLL peptide (Table 4). All three HLA-B*2705 ligands and 507 
the A10L614-623 HLA-A*0201-restricted ligand identified in our study were 508 
hydrophilic, with negative GRAVY values (Table 4). Only the vaccinia virus 509 
HLA-Cw1-restricted epitope D8L112-119, with a GRAVY value of 2.1, was 510 
hydrophobic. The other six ligands showed low positive GRAVY values, 511 
indicating low hydrophobicity (Table 4). The GRAVY mean of these eleven 512 
vaccinia ligands was only 0.3, which was very different from the EBV epitopes 513 
and more similar to the TAP-dependent vaccinia epitopes (Table 4). These 514 
results show that hydrophobicity is not a necessary condition for the TAP-515 
independent presentation of ligands/epitopes from other viruses such as 516 
vaccinia. 517 
 518 
Recognition of HLA-A*0201 ligands by specific CD8+ T cells in HLA 519 
transgenic mice immunized with vaccinia virus. 520 
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 To study the immunogenicity of the identified HLA-A*0201 viral ligands, 522 
transgenic HLA-A*0201-positive mice were immunized with VACV. Later, 523 
physiological measure of the functional in vivo activity of CD8+ T lymphocytes 524 
against HLA-A2 viral ligand identified by mass spectrometry was carried out. 525 
HLA-A*0201-transgenic mice eliminated VACV peptide-pulsed CFSEhigh cells 526 
when they had been previously immunized but not with uninfected control 527 
VACV (Fig. 6). In addition, up to 30 days post-immunization, polyclonal CTL 528 
lines were generated that were monospecific for each HLA-A2 viral ligand 529 
identified by mass spectrometry. These CTL lines specifically recognized 530 
peptide-pulsed cells (Fig. 7), indicating that the HLA ligands were all A*0201-531 
restricted CTL epitopes and that they were simultaneously recognized as part of 532 
the long-term memory response to vaccinia virus. Also, these CD8+ effector 533 
lines also specifically recognized VACV-infected cells (Figure 7D).  534 
Several attempts to induce CTL responses in HLA-B*2705 transgenic 535 
mice against the viral B*2705-restricted ligands identified were unsuccessful. 536 
This was also the case for the influenza NP epitope previously described in flu-537 
infected B27+ humans (67) that we used as a CTL-positive control. The mouse 538 
model used carried HLA-B27 and endogenous murine H2 class I molecules 539 
(27), in contrast to the HLA-A2 transgenic mouse knockout used previously for 540 
these mouse molecules (51). This may reduce the efficiency of HLA-restricted 541 
Ag-specific responses to undetectable levels (10) although the T cell repertoire 542 
as limiting factor could not be discarded. Unfortunately, HLA-B27 transgenic 543 
mice deficient for H2 class I expression (10) were not available. Therefore, the 544 
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study of HLA-B*2705-restricted CTL responses against vaccinia virus ligands 545 
was not feasible. 546 
 547 
 Three different antigen processing pathways were involved in 548 
the presentation of A10L688-696 and A17L9-17 epitopes in infected TAP-549 
sufficient cells.  550 
 551 
To study the antigen processing pathways involved in the endogenous 552 
generation of the A10L688-696 and A17L9-17 viral epitopes, we investigated the 553 
presentation of these epitopes to specific CTL in the presence of diverse 554 
protease inhibitors in VACV-infected TAP-sufficient cells.  555 
First, to demonstrate that these HLA-A2-restricted epitopes require 556 
endogenous processing, their presentation was analyzed in the presence of 557 
BFA. This drug blocks class I export beyond the cis-Golgi compartment (38), 558 
thus preventing the surface expression of newly assembled HLA class I-peptide 559 
complexes from endogenous origin (Table 1 summarizes the specificity of all 560 
inhibitors used). The complete inhibition of specific lysis in both specific CTL 561 
lines caused by the addition of BFA during vaccinia infection (Fig. 8A) 562 
demonstrated that the two relevant epitopes were indeed generated from 563 
proteins endogenously processed in infected cells. 564 
Lactacystin (LC), a Streptomyces metabolite (18),(48) was used to study 565 
the involvement of the proteasome in the presentation of these epitopes. This 566 
drug had no effect on the specific recognition of target cells infected with VACV 567 
by A10L688-696- or A17L9-17-specific CTLs (Fig. 8A). Although the proteasome 568 
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may be involved in the antigen processing of these epitopes, these data 569 
suggest that the LC-inhibitable proteasome activity is not absolutely required. 570 
Because several endogenous TAP-independent HLA-2 class I ligands 571 
are derived by cleavage of the signal sequences generated by the signal 572 
peptidase (SPase) complex (35),(70) and because no specific inhibitor of this 573 
enzymatic activity was available, the involvement of SPase complex in A17L9-17 574 
ligand production could not be studied directly. SPase-processed peptides need 575 
further cleavage by signal peptide peptidase (SPPase) (69),(68),(41). Therefore, 576 
the involvement of SPPase in antigen presentation was tested by treating target 577 
cells with the SPPase-specific inhibitor (z-LL)2 ketone (69)
,(68){. Similarly to LC, 578 
the inhibition of specific presentation was not detected with this drug (Fig. 8A). 579 
To identify proteases distinct from the proteasomes that could contribute 580 
to antigen processing of both HLA-A2 epitopes, experiments with several 581 
specific protease inhibitors were performed. Leupeptin (LEU) {Umezawa, 1976 582 
19523 /id}, pepstatin (PEPST) (33),(65) and 1,10-phenanthroline (PHE) 583 
(33),(64) were initially tested because they specifically inhibit different protease 584 
families (Table 1), thereby covering a wide range of proteases. Figure 8A shows 585 
that these three inhibitors had no effect on the specific recognition of target cells 586 
infected with VACV. In addition, because the activity of ERAAP, an enzyme 587 
involved in antigen processing (59),(72), is not fully blocked by PHE at the 588 
concentration used in this study, leucinethiol (LeuSH) (Table 1) (61) was also 589 
included. Like the other protease inhibitors, LeuSH did not inhibit the recognition 590 
of infected cells (Fig. 8A), indicating that ERAAP cannot be involved in the 591 
generation of these TAP-independent epitopes.  592 
 27 
In summary, the inhibitors used did not block the presentation of the two 593 
viral epitopes tested. The two most likely explanations for these results are as 594 
follows. First, these epitopes could be processed by protease(s) that not were 595 
blocked by the collection of inhibitors used in Figure 8A. This explanation is not 596 
likely because the inhibitors were chosen to cover a wide range of protease 597 
classes. Alternatively, these epitopes could be processed in parallel by different 598 
proteases independently, meaning that the different antigen processing 599 
pathways would need to be inhibited at the same time to see an effect. To test 600 
this hypothesis, the effects of combinations of several inhibitors on antigen 601 
presentation in vaccinia infected cells were tested. 602 
Because most class I epitopes are generated by proteasome activity, the 603 
presentation of these epitopes was analyzed in the presence of LC, together 604 
with each other inhibitor in turn. Figure 8B shows that the combination of LC 605 
with (z-LL)2 ketone, LEU, or PEPST did not block presentation in infected cells. 606 
In contrast, a partial block of presentation was observed in target cells treated 607 
with LC and PHE (Fig. 8B). These results demonstrate that the A10L688-696 and 608 
A17L9-17 peptides were processed by both metalloproteases and proteasomes 609 
in vivo. Additionally, the antigen presentation of both epitopes was partially 610 
inhibited by the combination of LC and LeuSH, indicating that ERAAP or other 611 
metallo-aminopeptidases were involved in the generation of these viral 612 
epitopes. Metallopeptidases can be divided into aminopeptidases, 613 
endopeptidases, carboxypeptidases, and carboxy-dipeptidases, among others, 614 
based on their cleavage mechanism (reviewed in (54)). Some of these groups 615 
can be distinguished by the use of different specific inhibitors (summarized in 616 
Table 1). To more precisely identify the metallopeptidase group involved in both 617 
 28 
A10L688-696 and A17L9-17 antigen processing, target cells were infected with 618 
VACV and treated with a mixture of LC and different specific inhibitors (Table 619 
1). The caspase-1-specific inhibitor z-VAD.fmk was also included in view of the 620 
sensitivity of this cysteine protease to PHE. Remarkably, none of the different 621 
combinations of inhibitors tested prevented antigen presentation to specific 622 
CTLs (Fig. 8B). Because phosphoramidon is able to inhibit bacterial 623 
endopeptidases but does not block all metallo-endopeptidases of mammalian 624 
origin, the most likely explanation for our results is that mammalian metallo-625 
endopeptidases that are not blocked by phosphoramidon are involved in the 626 
antigen processing of these viral epitopes. Over 100 different well-characterized 627 
higher vertebrate metallo-endoproteases are resistant to this drug (6); therefore, 628 
positive identification of the peptidase involved the processing of TAP-629 
independent vaccinia epitopes awaits further characterization. 630 
To demonstrate that two different metalloproteases, amino and endopeptidases, 631 
were independently involved in the generation of the A10L688-696 and A17L9-17 632 
epitopes, their presentation was analyzed in the presence of a mixture of PHE 633 
and LeuSH. The incomplete block detected in presentation indicates that 634 
aminometalloproteases and metallo-endopeptidases are independently needed 635 
to process both the A10L688-696 and A17L9-17 epitopes (Fig. 8B). Lastly, the 636 
recognition of infected cells by specific CTL was abrogated in the presence of 637 
three inhibitors: LC, PHE and LeuSH (Fig. 8B).  To exclude that the inhibitory 638 
effects of LC, PHE or LeuSH were due to toxic effects on target cells or on rVV 639 
replication, rather than to a specific block of the respective proteases, similar 640 
experiments in the same target cells to those shown in Fig. 8B were performed 641 
in parallel using the VACV-OVA257–264 which codes for the miniprotein 642 
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MSIINFEKL. Specific recognition by SIINFEKL-specific CTL of target cells 643 
infected with the VACV-OVA257–264 virus (64 ± 11 % of CD8
+ cells secreted 644 
IFNγ) was detected. In contrast, VACV-OVA257–264-infected target cells 645 
incubated with all combinations of these three inhibitors were efficiently 646 
recognized by SIINFEKL-specific CTL and no inhibition was detected (hatched 647 
bars in Fig. 8B). These data indicate that inhibition of the A10L688-696 and A17L9-648 
17 epitopes by addition of LC, PHE and LeuSH drugs is formally due to specific 649 
blockage of the respective proteases and not to a block in rVV replication or 650 
other toxic effects. 651 
In summary, the proteasome, aminometalloproteases, and metallo-652 
endopeptidases are all independently involved in the antigen processing of both 653 
A10L688-696 and A17L9-17 epitopes. The existence of identical neighboring 654 
residues around both the A10L688-696 and A17L9-17 sequences (Fig. 8C) could 655 
explain the similarity of the antigen processing pathways identified in these two 656 




The results reported here show an exceptional diversity of TAP-660 
independent ligands, with eleven ligands processed and presented as part of 661 
thirteen different HLA/peptide complexes simultaneously in VACV-infected cells. 662 
All three of the identified HLA-A2 ligands generated long-term CTL memory 663 
responses against vaccinia virus in a transgenic mouse model. Proteasomal 664 
and non-proteasomal pathways were involved in the processing and 665 
presentation of two vaccinia virus-encoded HLA-A2-restricted antigens. 666 
Identification of viral HLA ligands by mass spectrometry analysis 667 
contributes to a better understanding of the cellular antiviral immune response. 668 
However, the mass spectrometry strategies to identify such ligands have not 669 
become routine because of the difficulty in selecting and identifying the very 670 
limited number of viral sequences among the large number of self-peptides 671 
bound to HLA class I molecules. Therefore, the number of studies on viral HLA 672 
ligands is still limited. To date, only two studies have identified vaccinia virus 673 
ligands by mass spectrometry (45),(25). Currently, we identified three to four 674 
TAP-independent ligands that were processed and presented by each of the 675 
four class I molecules expressed in infected cells. Neither HLA-specific elution 676 
nor CTL responses have previously been reported in TAP+ cells for ten of the 677 
ligands identified in our study. However, as all three TAP-independent HLA-678 
A*0201 ligands also generated responses in TAP+ HLA-A*0201-transgenic 679 
mice, these epitopes must also be generated in wild-type cells.  680 
 31 
We detected HLA ligands from viral gene products expressed in the three 681 
gene expression temporality clusters of the viral life cycle (Supplemental Table 682 
1), early (A50R, B8R, C11R, and D5R), early/late (K2L), and late (A10L, A17L, 683 
and D8L), in agreement with a previous study investigating the CTL response in 684 
the same virus strain (52). Similar to the TAP+ response, the TAP-independent 685 
response also sampled proteins from the entire viral life cycle of the VACV WR 686 
strain. Other authors reported the absence of presentation of peptides derived 687 
from late viral Ags to specific T cells by infected mouse target cells (28),(45), but 688 
a different VACV strain was used in their studies. The sequences we identified 689 
were derived from eight different vaccinia virus proteins (Supplemental Table 1). 690 
Five of these proteins present signal sequence or transmembrane domains in 691 
their respective amino acid sequences and are therefore accessible to HLA-692 
containing compartments where they could be processed by resident proteases. 693 
In contrast, for three vaccinia proteins, A10L, A50R, and D5R, no obvious TAP-694 
independent antigen presentation could be predicted. However vaccinia DNA 695 
replication is associated with the cytoplasmic side of the rough ER, and when 696 
the replication proceeds, ER membranes are recruited (reviewed in (60)). Late 697 
in infection, the ER envelope is disassembled, and these membranes are 698 
recycled to the ER (reviewed in (60)). During this complex process that includes 699 
deep membrane reorganization, some molecules of A10L, A50R, and D5R 700 
proteins could gain access to a TAP-independent antigen processing pathway. 701 
In most cases, the identified natural MHC class I ligands had the 702 
canonical anchor motifs, and their respective antigenicity and MHC class I 703 
binding affinity were correlated. This suggests that only high-affinity peptides 704 
are recognized by CTLs and that epitopes of low affinity may be 705 
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immunologically irrelevant. We have demonstrated that cytotoxic responses are 706 
targeted against both high- and low-affinity HLA-A*0201 ligands of VACV; 707 
therefore, the TCRs of individual CTLs specific for low-affinity epitopes must 708 
display a compensatory high affinity. In addition, it has been reported that low-709 
affinity self-peptides in autoimmunity (reviewed in (15)) or tumor peptides (3) 710 
generate specific responses. These findings suggest that the range of peptides 711 
that can generate CTLs is broader than formerly considered and that the role of 712 
low-affinity epitopes in antiviral responses must be evaluated in future studies. 713 
Different MHC class I alleles have different TAP dependencies. The 714 
widespread HLA-A2 allele is considered to be the least TAP dependent (63). 715 
Alleles such as HLA-B7 and –B8 can also bind ligands that are dependent on 716 
mechanisms other than TAP transport, while other MHC class I molecules, 717 
including HLA-A3, -A24, and –B27, have been described as mainly TAP 718 
dependent (2). In the present report, several TAP-independent ligands were 719 
identified for alleles with different TAP requirements. Thus, the overall 720 
expression of MHC class I molecules with endogenous bound peptides is not 721 
indicative of specific TAP-independent cellular responses, which must be 722 
studied individually in each specific virus. 723 
Although TAP-independent viral epitopes are known (reviewed in 724 
(12),(26),(35)), only one epitope has been identified as the target of a specific 725 
antiviral CTL response in most of the cases studied. No systematic studies of 726 
TAP-independent pathways with a single virus and different HLA molecules 727 
have been reported. The exception is EBV, for which CTLs from different 728 
donors recognize several viral epitopes from two different viral proteins 729 
restricted by several HLA class I molecules in TAP-negative cell backgrounds 730 
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(reviewed in (37)). Here, we report a second case with eleven ligands from eight 731 
different viral proteins presented by four different HLA class I molecules in the 732 
same TAP-deficient vaccinia-infected cells. The simultaneous presentation of 733 
this broad complexity of viral peptide/MHC complexes can help to explain why 734 
TAP-deficient patients do not seem particularly susceptible to viral infections 735 
and may appear asymptomatic for long periods of their lives. In addition, the 736 
existence of multiple TAP-independent ligands in two very different viruses, a 737 
gamma-herpes virus and an orthopoxvirus, suggests that these pathways could 738 
be an extended, but perhaps secondary, mechanism that forms part of the 739 
multiple layers of defense against viral infection and that the significance of 740 
these alternative processing pathways in vivo needs to be further studied. 741 
The involvement of the following proteases in the processing of 742 
endogenously synthesized antigens, independently of the classical proteasome 743 
pathway, has been reported previously (reviewed in (11)). In the present report, 744 
two HLA-A2-restricted epitopes could be processed in parallel by amino 745 
metallo-peptidases as well as metallo-endoproteases and a classic proteasomal 746 
pathway.  747 
In addition to the A17L9-17 epitope previously described in TAP-sufficient 748 
cells (4), two distinct peptide epitopes recognized by human HLA-A2-restricted 749 
CD8+ T cells and eight HLA-B27, -B51, and/or –Cw1 ligands were newly 750 
detected in this study. Nine of the viral ligands identified are conserved in all 751 
three vaccinia virus strains, seven orthopoxviruses (including cowpox virus) and 752 
two variola strains. In contrast, only 60% of the previously described vaccinia 753 
virus epitopes are identical in the variola proteome (49),(52),(45). Therefore, 754 
TAP-independent vaccinia ligands are more highly conserved than TAP-755 
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dependent epitopes between immunogenic and pathologic poxviruses and 756 
could be more specific targets for immunization. Cowpox virus, the first 757 
component of early vaccines, specifically inhibits TAP-dependent peptide 758 
translocation(1); therefore, TAP-independent epitopes conserved between 759 
variola and this virus are probably responsible for the initial cross-protection. 760 
Additionally, truncated gene fragments similar to TAP-blocking CPXV12 protein 761 
are widely found in poxviral genomes (Poxvirus Bioinformatics Resources 762 
Center, http://www.poxvirus.org) and frequently represent loss-of-function 763 
phenotypes, but this “genetic debris” might acquire entirely new, unanticipated 764 
functions. Therefore, the conservation of epitopes between different vaccine 765 
strains and pathogens is relevant for vaccine design and suggests that ligands 766 
from TAP-independent pathways could be interesting candidates to be included 767 
in immunization protocols. This is also important with respect to bioterrorism 768 
because some countries did not participate in the WHO smallpox eradication 769 
program, and at the present time, no information about the elimination of their 770 
samples of the pandemic virus has been reported. 771 
Computational methods for predicting MHC-peptide binding are 772 
increasingly being used to identify epitopes for vaccine design and to monitor T 773 
cell responses (reviewed in (34),(43)). The prediction of MHC-peptide binding is 774 
far from perfect, as our results indicate. The prediction by bioinformatics tools of 775 
HLA class I molecules presenting the nine vaccinia viral ligands identified in 776 
current study showed several different mistakes, including incomplete HLA 777 
identification (K2L16-30 and C11R101-110 ligands), ambiguous HLA restriction 778 
(D5R148-157 and A17L9-25 ligands) or the wrong assignation (A10L614-623 and 779 
D8L112-119 ligands) (Table 5). In summary, more than half of these ligands 780 
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showed inconsistencies between the computational predictions and 781 
experimentally detected HLA restriction. These results reveal the limitations of 782 
predictive methods for identifying natural MHC class I ligands and T cell 783 
epitopes. The current analytical algorithms may not be sufficiently accurate and 784 
should be used with caution. 785 
Collectively, the results in the current report highlight the importance of 786 
analyzing natural peptides that result from the endogenous processing of viral 787 
proteins and demonstrate the complexity and plasticity of MHC-peptide 788 
interactions. This analysis is of fundamental importance for gaining a detailed 789 
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Specificity and activity of the inhibitors used in this study 
 
Inhibitor Abbreviation Specificity Reference Concentration 
% Inhibition of 
degradation a 
     
 
Brefeldin A BFA Vesicle transport  (71),(47) 5 g/ml ND
  
Lactacystin LC Proteasome  (18),(48) 10 M ND 
(z-LL)2 ketone z-LL2 Signal peptide peptidase (69)
,(68) 100 M 13 ± 4 
Leupeptin LEU Trypsin-like proteases and cysteine proteases (65) 100 M 38 ± 18 
Pepstatin PEPST Aspartic proteases (33),(65) 100 M 50 ± 5 
1-10 Phenanthroline PHE Metalloproteases and caspase-1 (33),(64) 50 M ND 
Leucinethiol LeuSH Metallo-aminopeptidases including ERAAP  (61) 30 M ND 
Benzyl Succynil Acid BENZ Metallo-carboxypeptidases A & B (33) 100 M -10 ± 8 
Captopril CAPT ACE and ACE-like proteases (33) 100 M 25 ± 2 
Phosphoramidon PHOSP 
All bacterial metallo-endopeptidases but few 
of mammalian origin 
(21),(33) 100 M 15 ± 4 
z-VAD.fmk z-VAD Caspases (62) 100 M ND 
b
 
     
 
 
a  Activity of these inhibitors was measured as their ability to prevent proteolytic degradation in cellular extracts as in reference (39). 
The amount of protein still present after incubation in the case of the degraded control sample was considered as 0 % inhibition of 
degradation, and the non-degraded unincubated sample was taken as 100 % inhibition. Data are mean of two independent 
experiments. Negative values indicate that there was enhanced degradation in the presence of the compound. ND, not done. 
 




Summary of HLA molecules bound by vaccinia virus epitopes 
 




    
A17L 9-17 MLDDFSAGA PA2.1  +
 b ND ND ND 
A10L 614-623 SPEGEETII PA2.1  + ND ND ND 
A10L 688-696 ILDRIITNA PA2.1  + ND ND ND 
A10L 867-876 SRGYFEHMKK ME1 ND
 C + ND ND 
B8R 53-59 WQTMYTN ME1 ND + ND ND 
K2L 16-30 YRLQGFTNAGIVAYK ME1 / W6-32 - + - + 
D5R 148-157 IAMKRTLLEL W6-32 - ND + - 
A50R 294-301 LPFGSLGI W6-32 - ND + - 
C11R 101-110 IPSPGIMLV W6-32 - ND + + 
A17L 9-25 MLDDFSAGAGVLDKDL W6-32 - ND - + 
D8L 112-119 DGLIIISI W6-32 - ND - + 
  
 
    
  
 
      
  
 
      a The mAbs used for the sequential immunoprecipitations were PA2.1 (specific for HLA-A2), ME1 (specific for HLA-B27), and W6/32 
(specific for a monomorphic HLA-A, B, C determinant). 
b A significant difference (P < 0.001) compared with the negative controls. 




















       
VACV WR MLDDFSAGA SPEGEETII ILDRIITNA SRGYFEHMKK WQTMYTN YRLQGFTNAGIVAYK 
VACV Copenhagen --------- --------- --------- ---------- ------- --------------- 
VACV MVA --------- --------- --------- ---------- ------- --------------- 
Variola major --------- --------- --------- ---------- ------- --------------- 
Variola minor --------- --------- --------- ---------- ------- --------------- 
Camelpox --------- --------- --------- ---------- ------- --------------- 
Cowpox --------- --------- --------- ---------- ------- --------------- 
Ectromelia virus --------- --------- --------- ---------- ------- --------------- 
Horsepox --------- --------- --------- ---------- ------- --------------- 
Monkeypox --------- --------- --------- ---------- ------- --------------- 























      
VACV WR IAMKRTLLEL LPFGSLGI IPSPGIMLV MLDDFSAGAGVLDKDL DGLIIISI 
VACV Copenhagen ---------- -------- --------- ---------------- -------- 
VACV MVA ---------- -------- --------- ---------------- -------- 
Variola major ---------- -------- ------V-- ---------------- -------- 
Variola minor ---------- -------- ------V-- ---------------- -------- 
Camelpox ---------- -------- ------V-- ---------------- -------- 
Cowpox ---------- -------- ------V-- ---------------- --I--VA- 
Ectromelia virus ---------- -------- --------- ---------------- -------- 
Horsepox ---------- -------- --------- ---------------- -------- 
Monkeypox ---------- -------- ---L--V-- ---------------- --I---A- 














TAP-independent ligands/epitopes and their hydrophobicity. 
 
 
Ligand/epitope Protein Virus Hydrophobicitya Reference 
     
LLWTLVVLL LMP2 EBV 2.9 (37) 
CLGGLLTMV LMP2 EBV 2.1 (37) 
     
Mean ± SD of  
8 TAP- epitopes 
 EBV 2.5 ± 0.2 (37) 
     
MLDDFSAGA A17L9-17 Vaccinia 0.4 This study 
SPEGEETII A10L614-623 Vaccinia -0.6 This study 
ILDRIITNA A10L688-696 Vaccinia 0.8 This study 
SRGYFEHMKK A10L867-876 Vaccinia -1.7 This study 
WQTMYTN B8R53-59 Vaccinia -1.2 This study 
YRLQGFTNAGIVAYK K2L16-30 Vaccinia -0.1 This study 
IAMKRTLLEL D5R 148-157 Vaccinia 0.7 This study 
LPFGSLGI A50R 294-301 Vaccinia 1.5 This study 
IPSPGIMLV C11R 101-110 Vaccinia 1.6 This study 
MLDDFSAGAGVLDKDL A17L 9-25 Vaccinia 0.3 This study 
DGLIIISI D8L 112-119 Vaccinia 2.1 This study 
     
Mean ± SD of  
11 TAP- ligands 
 Vaccinia 0.3 ± 1.2 This study 
     
  P value < 0.0001  
     
Mean ± SD of  
79 TAP+ epitopes 
 Vaccinia 0.4 ± 1.0 (45),(25) 
     
 
 
a as measured on the grand average of hydropathicity (GRAVY) scale (ProtParam 







Comparison between predicted and experimentally detected binding of vaccinia virus 







    
A17L 9-17 MLDDFSAGA -A2 -A2 
A10L 614-623 SPEGEETII -B51 -A2 
A10L 688-696 ILDRIITNA -A2 -A2 
A10L 867-876 SRGYFEHMKK -B27 -B27 
B8R 53-59 WQTMYTN -B27 -B27 
K2L 16-30 YRLQGFTNAGIVAYK -B27 -B27 / -Cw1 
D5R 148-157 IAMKRTLLEL -B51 / -Cw1 -B51 
A50R 294-301 LPFGSLGI -B51 -B51 
C11R 101-110 IPSPGIMLV -B51 -B51 / -Cw1 
A17L 9-25 MLDDFSAGAGVLDKDL -A2 / -Cw1 -Cw1 
D8L 112-119 DGLIIISI -B51 -Cw1 
    
 
a From the SYFPEITHI (http://www.syfpeithi.de), BIMAS (http://www-












W6/32 (α-HLA class I)
HLA-B51/β2m/peptides
HLA-Cw1/β2m/peptides
Lorente et al. Figure 1 
Diagram of sequential immunoprecipitation. 
 
4 x 1010 healthy or VACV-infected T2-B27 transfectant cells were lysed. HLA-
peptide complexes were isolated via affinity chromatography of the soluble 
fraction of cell extracts with the following mAbs, used sequentially: PA2.1 (anti-
HLA-A2), ME1 (anti-HLA-B27), and W6/32 (specific for a monomorphic HLA 
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Lorente et al. Figure 2
***
Recognition of TAP+ and TAP– cell lines by VACV-specific CD8+ T
lymphocytes. 
 
HLA-A*0201 TAP+ (RMA, left panel) and TAP– (RMA-S, right panel) cells were 
infected with VACV at a multiplicity of infection of 40 plaque-forming units/cell 
and analyzed by ICS for CD8+ T cell activation. The results are calculated as 
the mean of three or four independent experiments ± SD. *** Significant P 
values (P < 0.0001). 



































HLA-A*0201 stabilization assay with synthetic VACV ligands. 
 
The stability of HLA-A*0201/peptide complexes on the surface of RMA-S
transfectant cells was measured by flow cytometry. The indicated peptides were 
used at 200 µM (panel A). The mAb used was the monoclonal PA2.1. Panel B: 
The titration curves for synthetic VACV A17L9-17 (triangles), A10L614-623
(diamonds), and A10L688-696 (circles) peptides with HLA-A*0201 are depicted. 
The C4CON (solid line) and KPNA2 (squares) peptides were used as negative 
and positive controls, respectively. The results, calculated as the fluorescence 
index (panel A), are the mean of three or four independent experiments. The 
calculated EC50 values ± SD are shown in panel B. 






































HLA-B*2705 stabilization assay with synthetic VACV ligands. 
 
The stability of HLA-B*2705/peptide complexes on the surface of RMA-S
transfectant cells measured by flow cytometry. The indicated peptides were 
used at 200 µM (panel A). The mAb used was the monoclonal ME1. Panel B: 
The titration curves for synthetic VACV A10L867-876 (triangles), K2L16-30
(diamonds), and B8R53-59 (circles) peptides with HLA- B*2705 are depicted. The 
C4CON (solid line) and Flu NP (squares) peptides were used as negative and 
positive controls, respectively. The results, as in Figure 2, are the mean of four
independent experiments.  

































































































Lorente et al. Figure 5 
HLA class I stabilization assay of synthetic VACV ligands. 
The stability of HLA-A2 (panel A), -B51 (panel B), and -Cw1 (panel C) at the cell surface of T2 TAP-deficient cells was measured by flow cytometry. The indicated
peptides were used at 200 µM. Titration curves for the indicated synthetic VACV peptides, immunoprecipitated with W6/32 Ab, with HLA-B51 (panel D) or –Cw1 (panel E)
are shown. The C4CON peptide was used as negative control (solid line). The HBV HBc19-27 and CMV pp657-15 peptides were used as positive controls for binding to the
HLA-B51 and –Cw1 alleles, respectively. The Abs used were monoclonal PA2.1 (anti-HLA-A2, panel A), polyclonal H00003106-B01P (anti-HLA-B class I molecules, panel
B, D), and polyclonal SC-19438 (anti-HLA-C class I molecules, panel C, E). The results, as in Figure 2, are the mean of four to six independent experiments. 
(µM)
(µM)
In vivo killing activity of VACV peptide-specific CTLs in HLA-A*0201-
transgenic mice. 
 
HLA-A*0201-transgenic mice were infected i.p. with VAVC. One week later, 
they were injected i.p. with syngeneic splenocytes either unpulsed and labeled 
with low CFSE (none) or pulsed with the indicated VACV peptides and labeled 
with high CFSE. Two days later, remaining CFSE-labeled target cells in the 
peritoneal cavity were lavaged and analyzed by flow cytometry. Percent in vivo 














































Recognition of VACV epitopes presented by the HLA-A*0201 class I 
molecule by CTLs. 
 
RMA-HLA-A*0201 target cells pre-pulsed with 10-5 M A17L9-17 (panel A),
A10L614-623 (panel B), and A10L688-696 (panel C) synthetic peptides were tested 
in a cytolytic assay with their respective memory peptide-specific CTL lines 
obtained from HLA-A*0201-transgenic mice immunized up to 30 days before 
with VACV (upper panel). The KPNA2 peptide was used as negative control 
(open circles).The data are the mean of at least three independent experiments.
HLA-A*0201 TAP+ cells were infected with VACV at a multiplicity of infection of 
40 plaque-forming units/cell and analyzed by ICS for CD8+ T cell activation with 
the HLA-A*0201 memory peptide-specific CTL lines (lower panel). The data are 














Lorente et al. Figure 8 
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Recognition of target cells infected in the presence of inhibitors. 
 
RMA-HLA-A*0201 target cells infected for 16 hr with VACV or VACV-OVA257–264
at a multiplicity of infection of 40 plaque-forming units/cell were treated with the 
indicated inhibitors. An ICS assay was used to test for recognition by A10L688-
696- (open bars), A17L9-17- (closed bars) or SIINFEKL-specific (hatched bars)
CTLs. The percentage of specific inhibition obtained by the addition of the 
indicated single (panel A) or mixture of two or three (panel B) inhibitors was 
calculated as: 
[(ICS VACV + Inhibitor) – ICS without infection]  
% Specific Inhibition = 100  -        ---------------------------------------------------------------   x 100 
      ICS VACV – ICS without infection 
 
and the data displayed is the mean ± SD of 4-6 independent experiments.
Panel C: the sequence of the neighboring residues to the epitopes in A10L and 
A17L proteins. The sequence of each epitope is boxed. Identical residues in 
both sequences are bolded. 
Supplemental Table 1 
Major characteristics of HLA ligand-containing vaccinia proteins a 
 
Protein  Name Expression Signal sequence 
Transmembrane 
domains 
Encapsidated pI Mw PTM b 
Essential 
 to VACV 
          
A10L P4a precursor Late None 0 Yes, in core 6.1 102 
 
NI c 
A17L IMV membrane protein  Late Putative 4 
Yes, in 
membrane 
4.4 23 Phosphorylation Yes 
A50R DNA ligase Early None 0 No 7.9 63 
 
No 
B8R IFN-gamma receptor Early Putative 0 No 5.5 31 
 
NI 
C11R EGF growth factor Early Putative  1 No 6.4 16 
 
NI 
D5R NTPase Early None 0 No 6.8 90 
 
Yes 






K2L Serpin 1,2,3 Early/Late Putative  0 No 9.0 42 
 
NI 
          
 
a All information was obtained from the Poxvirus Bioinformatics Resources Center (http://www.poxvirus.org). 
b  PTM, post-translational modification. 
b NI, no information. 
 1 
SUPPLEMENTAL FIGURE LEGENDS 1 
 2 
Figure S1. VACV infection of the RMA-HLA-A*0201 cell line in presence of 3 
different protease inhibitors. 4 
 5 
RMA-HLA-A*0201 target cells infected for 16 hr with VACV at a multiplicity of infection 6 
of 40 plaque-forming units/cell were treated with the indicated inhibitors. A mock 7 
infected control was included as negative control. The cells were stained with the 8 
Omnitope antiserum-FITC that recognizes VACV purified virions. Samples were 9 
analyzed by FACS. The results, calculated as fluorescence index ± SD, are the mean 10 
of 4 independent experiments. The fluorescence index was calculated as the ratio of 11 
mean channel fluorescence of the sample to that of the control incubated without 12 
VACV. All VACV-infected conditions (with and without inhibitors) show significant P 13 
values (P < 0.01) versus mock infected controls. In contrast, all inhibitor conditions 14 
show non significant P values versus VACV-infected control without an inhibitor. 15 
 16 
Figure S2. Identification of three HLA-A*0201 ligands in infected cell extracts by 17 
mass spectrometry.  18 
  19 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 20 
the ion peaks at m/z 926.4 (upper left panel), m/z 974.6 (medium left panel), and m/z 21 
514.8 (lower left panel) from the VACV-infected cell extract and the corresponding 22 
synthetic peptide (right panels). The vertical axis represents the relative abundance of 23 
the parental ion and each fragmentation ion detected. The horizontal axis corresponds 24 
to the m/z region in which significant daughter ions were detected. Ions generated by 25 
the fragmentation are detailed, and the sequence deduced from the indicated 26 
fragments is shown in the upper left box of each panel. 27 
 28 
 2 
Figure S3. Identification of three HLA-B27 ligands in infected cell extracts by 29 
mass spectrometry.  30 
  31 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 32 
the ion peaks at m/z 428.2 (upper left panel), m/z 567.6 (medium left panel), and m/z 33 
472.1 (lower left panel) from the VACV-infected cell extract and the corresponding 34 
synthetic peptide (right panels). The axes are as described in Figure S1. 35 
 36 
Figure S4. Identification of three HLA ligands in infected cell extracts by mass 37 
spectrometry (I).  38 
  39 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 40 
the ion peaks at m/z 594.4 (upper left panel), m/z 803.5 (medium left panel), and m/z 41 
926.5 (lower left panel) from the VACV-infected cell extract and the corresponding 42 
synthetic peptide (right panels). The axes are as described in Figure S1. 43 
 44 
Figure S5. Identification of three HLA ligands in infected cell extracts by mass 45 
spectrometry (II).  46 
  47 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 48 
the ion peaks at m/z 843.5 (upper left panel), m/z 833.9 (medium left panel), and m/z 49 
851.0 (lower left panel) from the VACV-infected cell extract and the corresponding 50 
synthetic peptide (right panels). The axes are as described in Figure S1. 51 
 52 
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Lorente et al. Figure S3
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Lorente et al. Figure S5
experimentally detected synthetic
